Association of CYP2C19 gene polymorphism with anastrozole in treatment of postmenopausal breast can-cer patients
10.3969/j.issn.1006-5725.2018.03.030
- VernacularTitle:CYP2C19基因多态性与阿那曲唑治疗绝经后乳腺癌患者疗效的相关性
- Author:
Qianqian HOU
1
;
Lingling LI
;
Daqing WANG
;
Hu YANG
;
Wei GU
Author Information
1. 河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000
- Keywords:
postmenopausal breast cancer;
CYP2C19*2;
gene polymorphism;
anastrozole
- From:
The Journal of Practical Medicine
2018;34(3):460-463
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between CYP2C19*2 gene polymorphism and efficacy of anastrozole in postmenopausal women with breast cancer. Methods The polymorphisms of CYP2C19*2 gene in postmenopausal women with postmenopausal breast cancer were detected by PCR. Results The A allele frequency of the CYP2C19*2 gene(OR=3.146,95% CI:1.244~7.275,P<0.05)was a risk factor for the efficacy of post-menopausal breast cancer patients.The survival rate was lower than that of GG(χ2=6.26,P<0.05).After treat-ment,the FSH and LH of GG patients were significantly lower than those of AA and GA(t=5.29,6.47,P<0.05). Multivariate logistic regression analysis showed that anastrozoleand CYP2C19*2 gene polymorphism were indepen-dently associated with serum FSH and LH levels in postmenopausal women with breast. Conclusion CYP2C19*2 gene polymorphism is associated with anastrozole in the treatment of postmenopausal breast cancer.
